Arcturus Therapeutics Holdings Inc

NASDAQ:ARCT   10:56:49 AM EDT
31.47
+2.72 (+9.46%)
Products, Regulatory

Arcturus Therapeutics Gets Approval From Singapore Health Sciences Authority To Proceed With Phase 2 Study Of Arct-021 (Lunar-Cov19) Vaccine Candidate

Published: 12/28/2020 21:16 GMT
Arcturus Therapeutics Holdings Inc (ARCT) - Arcturus Therapeutics Received Approval From Singapore Health Sciences Authority to Proceed With Phase 2 Study of Arct-021 (lunar-cov19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data.
Arcturus Therapeutics Holdings Inc - Anticipate Interim Phase 2 Data in Early 2021; Targeting Global Phase 3 Study Start in Q2 2021.
Arcturus Therapeutics Holdings Inc - Phase 1/2 Data Demonstrates Favorable Tolerability.